GSK (GSK) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed GSK (GSK) over the past year, gaining 94.2% versus a gain of 7.4%. Over five years, TEVA leads with a +305.5% price change compared with +19.3% for GSK. GSK is the larger company by market cap ($93.24 billion vs $45.78 billion), about 2.0 times the size.
On valuation, GSK trades at a lower forward P/E (9.4x vs 12.7x for Teva Pharmaceutical Industries). GSK pays a dividend yielding 1.46%, while Teva Pharmaceutical Industries does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GSK | TEVA |
|---|---|---|
| Share price | $46.54 | $39.25 |
| Market cap | $93.24B | $45.78B |
| 1-day change | -1.02% | +0.18% |
| YTD return | -5.10% | +25.76% |
| 1-year return | +7.36% | +94.21% |
| 5-year return | +19.30% | +305.48% |
| P/E ratio (TTM) | 14.68 | 65.42 |
| Forward P/E | 9.42 | 12.70 |
| EPS (TTM) | $3.17 | $0.60 |
| Dividend yield | 1.46% | 0.00% |
| Annual dividend | $0.68 | $0.00 |
| Revenue (latest FY) | — | $17.26B |
| Revenue growth (YoY) | — | +4.32% |
| Net income (latest FY) | — | $1.41B |
| Gross margin | — | 51.79% |
| Operating margin | — | 12.50% |
| Net margin | — | 8.17% |
| 52-week high | $61.70 | $40.79 |
| 52-week low | $42.85 | $18.83 |
| Distance from 52-week high | -24.57% | -3.78% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +27.48% | +15.41% |
| Average volume | 3.85M | 5.29M |
| Shares outstanding | 2.00B | 1.17B |
| Employees | 66,841 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GSK is about 2.0 times larger than Teva Pharmaceutical Industries by market value ($93.24B vs $45.78B).
- TEVA has outperformed GSK by 86.9 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.4x vs 14.7x trailing P/E).
- GSK offers a meaningfully higher dividend yield (1.46% vs 0.00%).
About GSK
GSK stock →GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 66,841 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
GSK vs TEVA FAQ
Which is bigger, GSK or Teva Pharmaceutical Industries?
GSK (GSK) is larger, with a market capitalization of $93.24B compared with $45.78B for Teva Pharmaceutical Industries (TEVA).
Which stock has performed better over the past year, GSK or TEVA?
TEVA returned +94.21% over the past 12 months, compared with +7.36% for GSK (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GSK or TEVA?
GSK has the lower trailing P/E at 14.7, versus 65.4 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, GSK or Teva Pharmaceutical Industries?
GSK pays a dividend yielding 1.46%, while Teva Pharmaceutical Industries does not currently pay a regular dividend.
Are GSK and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.